From Russia (with love?) [RSABE / ABEL]

posted by PharmCat  – Russia, 2019-12-04 16:16 (2044 d 09:49 ago) – Posting: # 20924
Views: 10,569

Hello Helmut!

IMHO, main points:

1. Basic words. Review article.
2. ABEL/RSABE - all have TIE inflation.
3. Biggest inflation when CVintra = 25—30%.
4. EMA aproach better than FDA.

Conclusion:

When you are planning bioequivalence trial better look at EMA guidelines, rather than FDA. We know that all approaches have TIE inflation.

I think this is primarily a message to regulatory experts.

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,689 registered users;
46 visitors (0 registered, 46 guests [including 10 identified bots]).
Forum time: 03:05 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5